November 21, 2026

Glyconics©’ novel non-invasive diabetes screening device meets primary endpoints in two clinical investigations

placeholder

Award-winning medtech firm, Glyconics© has successfully completed two independent clinical studies to validate the performance and safety of its novel non-invasive diabetes screening device.

The currently embargoed ANODE01 and ANODE02 diabetes programme results will be formally announced at the annual meeting of the American Diabetes Association (ADA) in June.

Glyconics’ Chief Medical Officer, Dr Päivi Maria Paldánius said: “Diabetes kills prematurely more people than breast cancer and prostate cancer combined every year and is a major cause of debilitating, severe complications such as blindness, heart attack and stroke. Although early detection is recommended, mass-screening for diabetes is not implemented as it currently necessitates invasive blood sampling, tons of single-use plastics and complex, costly operations. The clinical implementation of these results – using a novel, non-invasive approach to screening – will now enable a more strategic allocation of limited healthcare resources for the management of global diabetes risk in the future.

“Based on these encouraging study outcomes in two diverse populations, we will continue our clinical programme with a third large-scale ANODE03 study later this year. We have been delighted to collaborate with two leading diabetes research centres, representing different types of healthcare systems – and with Professor Pratik Choudhary and Professor Xavier Cos, two of the world authorities on diabetes management, acting as lead investigators. Glyconics’ mission is to make a transformational impact on global diabetes management by developing accessible, affordable and sustainable population screening tools for diabetes screening.”

Dr Pratik Choudhary, Professor and Honorary Consultant in Diabetes at the University of Leicester and Leicester Diabetes Centre, said: “I am thrilled to have been involved in this very pragmatic early-stage clinical investigation. We can address global inequalities in health by developing more affordable, rapid and precise mass-screening tools and, thus, identify the millions with undiagnosed diabetes, especially in resource-constrained countries. It has been especially important to conduct this study in Leicester where screening within our ethnically diverse population is essential for the management of diabetes risk and early prevention.”

Prof Cos, Chairman of Primary Care Diabetes Europe and Associate Professor of Medicine at the Autonomous University of Barcelona and GP at Sant Martí de Provencals primary care centre, Institut Català de la Salut, Barcelona, said: “Developing non-invasive systems for population-level screening will be an important tool in reducing current barriers for mass-screening and identifying people at risk early – because early detection and treatment is key to better long-term outcomes. Clearly the early detection of elevated diabetes risk requires more attention and enables diabetes prevention – and this exciting new approach could shape the pivotal role that primary care plays in the management of diabetes and its long-term outcomes.”

About Glyconics©
Glyconics© is an innovative diagnostic company exploiting the use of miniaturised near-infrared (NIR) spectrometry and its ability to produce a distinctive molecular ‘fingerprint’ in healthy vs non-healthy samples using a predictive cloud-based algorithm in simple point-of-care devices. The technology has utility in clinical management and the development of Diabetes, COPD, Infectious Diseases (e.g., COVID) and other therapeutic areas and applications. Glyconics© has obtained ISO 13485 certification for its quality management system, a key stepping-stone to obtaining CE marking. www.glyconics.com

About ANODE study programme
The clinical ANODE diabetes programme marks a significant milestone for the game-changing Glyconics-SX™ point-of-care device, which exploits the use of miniaturised NIR spectrometry and cloud-based algorithms for an early, rapid, non-invasive screening for diabetes. The handheld device detects biomarker changes (glycated, ‘sugar-coated’, keratin) based on a few infrared scans of a person’s fingernail within seconds. The clinical ANODE programme, which started last July [2022] and closed in November, tested the safety and performance (accuracy) of NIR methodology in two independent studies, ANODE01 and ANODE02, conducted in Leicester, UK, and Barcelona, Spain, respectively. Each study involved 100 individuals with or without known type 2 diabetes, and assessment of their diabetes risk and status was based on a total of 12,000 NIR spectral scans of the participants’ middle fingernails on both hands. The studies evaluated the accuracy of the miniaturised NIR device in identifying individuals based on their confirmed glucose levels (glycated haemoglobin, HbA1c) indicative of diabetes status, by stress-testing its performance also in individuals with pre-diabetes and those with well-controlled, early diabetes whose glucose values are below the diagnostic range.

The ClinicalTrials.gov identifiers for the studies are NCT05198895 (ANODE01) and NCT05476016 (ANODE02). The combined results of the ANODE programme will be submitted in March to meet the incoming abstract deadline for the annual meeting of European Association of Study of Diabetes (EASD) taking place in September.